Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-06-30
2010-11-02
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S322000, C530S324000, C530S350000
Reexamination Certificate
active
07825085
ABSTRACT:
The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptors. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as a crucial element for the binding to viral-infected cells. The present invention provides peptides that are derived from the amino acid sequence of NKp46 receptor, capable of specific targeting of viral-infected cells and tumor cells and monoclonal antibodies which recognize a specific domain of NKp46. The present invention further provides hyperglycosylated peptides that are derived from the NKp44 receptor, capable of specific targeting of viral-infected cells.
REFERENCES:
patent: 5019368 (1991-05-01), Epstein
patent: 5134075 (1992-07-01), Hellstrom
patent: 5171665 (1992-12-01), Hellstrom
patent: 5196337 (1993-03-01), Ochi
patent: 5204095 (1993-04-01), Goodall
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5882626 (1999-03-01), Epstein
patent: 5965132 (1999-10-01), Thorpe
patent: 6004554 (1999-12-01), Thorpe
patent: 6017514 (2000-01-01), Epstein
patent: 6071491 (2000-06-01), Epstein
patent: 6342221 (2002-01-01), Thorpe
patent: 6703018 (2004-03-01), Jardieu
patent: 6719971 (2004-04-01), Carter
patent: 6723538 (2004-04-01), Mack
patent: 2006/0165592 (2006-07-01), Mandelboim
patent: 02/08287 (2002-01-01), None
patent: WO 02/08287 (2002-01-01), None
patent: 02/008287 (2002-12-01), None
patent: 2004/053054 (2004-06-01), None
patent: 2004/053054 (2004-10-01), None
Cantoni et al, The Journal of Experimental Medicine, 1999, vol. 189, No. 5, pp. 787.
Arnon et al., “The mechanisms controlling the recognition of tumor and virus infected cells by NKp46” Blood. 2004;103:664-672.
Biassoni et al, “Human natural killer cell receptors and co-receptors” Immunol Rev. 2001;181:203-214.
Cantoni et al., “NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily” J Exp. Med. 1999;189(5), 787-796.
Costello et al., “Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia” Blood. 2002;99:3661-3667.
Dennissen, et al., “Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies” J Biol Chem 2002;277:10982.
Lee et al., “Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase” J Biol Chem. 1989; 264:13848-13855.
Mandelboim et al., “Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity” Proc Natl Acad Sci U.S.A. 1999;96:5640-5644.
Mandelboim et al., “Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells” Nature. 2001;409:1055-1060.
Markel et al., “Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions” J Clin Invest. 2002;110:943-953.
Pende et al., “Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells” J Exp Med. 1999;190:1505-1516.
Pessino et al., “Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity” J Exp Med. 1998;188:953-960.
Skehel et al., “Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion” Proc Natl Acad Sci U S A. 1982;79:968-972.
Sivori et al., “p46, A novel natural killer cell-specific surface molecule that mediates cell activation” J Exp Med. 1997;186:1129-1136.
Vankayalapati et al., “The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium” J Immunol. 2002;168:3451-3457.
Vitale et al., “NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis” J Exp Med. 1998;187:2065-2072.
Mandelboim Ofer
Porgador Angel
Ben-Gurion University of the Negev Research and Development Auth
Bunner Bridget E
Hamud Fozia M
Winston & Strawn LLP
Yissum Research Development Company of the Hebrew University of
LandOfFree
Fragments of NKp44 and NKp46 for targeting viral-infected... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fragments of NKp44 and NKp46 for targeting viral-infected..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fragments of NKp44 and NKp46 for targeting viral-infected... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175885